In this issue:
Efficacy of loncastuximab
Acalabrutinib, bendamustine, and rituximab
Clinical outcomes and treatment patterns of asciminib
Benefit of obinutuzumab plus bendamustine
Safety and efficacy of BV
Role of IGH and IGK gene rearrangements
Glofitamab and gemcitabine-oxaliplatin
Nivolumab “priming” and subsequent nivolumab-rituximab
Acalabrutinib plus R2 for R/R FL
AVO in chronic lymphocytic leukaemia patients
Please login below to download this issue (PDF)